Apellis Swings to Profit on Strong Drug Sales, Eyes Future Growth

WALTHAM, MA – February 24, 2026 – Apellis Pharmaceuticals has achieved a significant corporate milestone, reporting its first full year of profitability in 2025. The biotech firm's transition from a nearly $200 million net loss in 2024 to a $22.4 million net income marks a pivotal moment, driven by the robust commercial performance of its two flagship therapies, SYFOVRE for a leading cause of blindness and EMPAVELI for rare diseases.

The company announced full-year net product revenues of $689 million, underpinning total revenues that crossed the $1 billion threshold, a figure bolstered by a one-time payment related to a collaboration agreement. With a fortified cash position of $466 million, management projects a clear path to sustained profitability without the need for additional capital raises, a rare feat in the cash-intensive biotech industry.

“2025 was a year of disciplined execution and meaningful progress across the business, and we enter 2026 with clear priorities and a strong foundation,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “We are focused on positioning SYFOVRE for its next phase of growth, maximizing EMPAVELI’s blockbuster opportunity in rare kidney diseases, and advancing a differentiated, self-funded pipeline leveraging our deep expertise in C3 biology.”

Despite the strong annual results, the journey shows signs of quarterly variability. The company posted a net loss of $58.9 million for the fourth quarter of 2025, and its stock saw a pre-market dip following the announcement, reflecting investor sensitivity to near-term revenue fluctuations and operational costs.

SYFOVRE's Market Dominance Faces Headwinds

The primary engine of Apellis's financial success remains SYFOVRE (pegcetacoplan injection), the first-ever approved therapy for geographic atrophy (GA), a progressive form of age-related macular degeneration that leads to irreversible vision loss. The drug generated $587 million in U.S. net product revenue in 2025, cementing its status as the market leader with an approximate 60% share.

Demand for the treatment remains strong, with total injections increasing by 17% year-over-year. However, the full-year revenue for SYFOVRE saw a modest dip from $611.9 million in 2024. This was attributed in part to an increased use of "free goods" programs designed to facilitate patient access, a factor that also contributed to a sequential softness in Q4 revenue. The company anticipates that gross-to-net adjustments for the drug will climb into the high-20% range in 2026, a metric investors will be watching closely.

The competitive landscape is also heating up. SYFOVRE faces a direct challenge from Izervay, a C5 inhibitor from Astellas Pharma that gained FDA approval in August 2023. While Apellis has highlighted SYFOVRE's convenient dosing schedule and strong five-year data showing a significant delay in GA progression, the market is no longer a monopoly. To maintain its edge, Apellis is innovating on the delivery front, planning a regulatory submission for a SYFOVRE prefilled syringe in the first half of 2026. This "practice-enabling" device aims to streamline workflow in busy retina clinics and could be a key differentiator.

Expanding the Complement Platform with EMPAVELI

While SYFOVRE captures headlines in ophthalmology, Apellis is executing a broader strategy built on its expertise in targeting the C3 protein of the complement system. This is most evident in the growing success of EMPAVELI (pegcetacoplan), which is approved for multiple rare diseases.

EMPAVELI brought in $102 million in U.S. net product revenue in 2025, but its future potential is what excites the company. Following its approval in mid-2025 for two rare kidney diseases, C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN), the drug has seen a remarkably strong early launch. Apellis reported that it achieved over 5% penetration of the estimated 5,000-patient U.S. market within its first full quarter, a launch pace that outstrips many other rare nephrology drugs. This rapid uptake is supported by favorable payer access, with 95% of published insurance policies covering the treatment with minimal restrictions.

Apellis is now aiming to expand EMPAVELI's reach even further. The company has initiated pivotal trials for two additional rare kidney diseases with high unmet need and no currently approved therapies: focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF). Success in these indications, which represent thousands of potential new patients annually in the U.S., could transform EMPAVELI into a blockbuster franchise in its own right and further validate the company's C3-targeting platform.

A Glimpse into the Future Pipeline and Investor Outlook

Looking beyond its currently marketed products, Apellis is advancing an innovative pipeline that could create significant long-term value. The most ambitious of these programs is APL-9099, a potential "one-and-done" treatment utilizing advanced base editing technology licensed from Beam Therapeutics. By targeting the neonatal Fc receptor (FcRn), APL-9099 aims to treat a range of autoimmune diseases by reducing IgG levels while preserving albumin, potentially disrupting a market estimated to be worth over $20 billion. An Investigational New Drug (IND) submission is planned for the second half of 2026.

This forward-looking strategy is critical as the company navigates a mixed investor landscape. While the full-year profitability is a major achievement, the high valuation of Apellis's stock—with a P/E ratio far exceeding industry averages—leaves little room for error. Analysts are largely bullish on the long-term story, with a majority holding 'Buy' ratings, but some remain skeptical. A Goldman Sachs analyst, for instance, maintains a 'Sell' rating, citing concerns about "limited near-term growth levers" for SYFOVRE.

The company's ability to manage its finances, including a $94 million convertible debt maturing in September 2026, while continuing to fund its ambitious R&D pipeline will be paramount. Apellis has successfully transitioned from a development-stage company to a commercial entity in the black, but its next chapter will depend on sustaining SYFOVRE's growth, maximizing EMPAVELI's rare disease potential, and successfully executing on its next generation of complement-based therapies.